Delving into the Latest Updates on NPS-4 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

NPS-4

Target-

Mechanism-

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Dermatitis

Originator Organization

NeoPharm Co., Ltd.

Active Organization-

Inactive Organization

NeoPharm Co., Ltd.

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

Smart and active nanoparticles are of increasing interest in food films and coatings application. In the current study, we purpose novel nanoparticles NPs-4_(1:5) and NPs-4_(1:5.5), which possess simultaneously both smart (temperature sensitive) and active (antibacterial, light absorbing and antioxidant) properties. The obtained nanoparticles are based on PEG/MC core with anthocyanidin and sodium acetate, and chitosan/gallotannin-based shell. The nanoparticles have hydrodynamic diameter ca. 450 nm and are positively charged (ζ-potential is 21 mV for NPs-4_(1:5) and +23 mV for NPs-4_(1:5.5). NPs-4_(1:5) and NPs-4_(1:5.5) are thermochromic and turn from colorless to purple at ca. 20 °C 0 °C respectively. The nanoparticles possess antibacterial activity much more than the starting chitosan (MIC, μg/mL, E. coli: 1.35 (NPs-4_(1:5)), 1.18 (NPs-4_(1:5.5)) and 10.12 (chitosan); S. aureus: 1.14 (NPs-4_(1:5)), 1.10 (NPs-4_(1:5.5)) and 6.20 (chitosan)). The nanoparticles efficiently absorb ultraviolet light, have high antioxidant effect (0.051 trolox equivalents), are non-toxic and fully composed of substances approved for use in the food industry.

01 Jan 2004·Current medical research and opinionQ4 · MEDICINE

Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale

Q4 · MEDICINE

Article

Author: Arnold R. Gammaitoni ; Charles E. Argoff ; Napoleon Oleka ; Mark P. Jensen ; Bradley S. Galer

OBJECTIVE:

To determine the impact of the lidocaine patch 5% on pain qualities associated with chronic pain from postherpetic neuralgia (PHN), painful diabetic neuropathy (DN), and low-back pain (LBP), using the Neuropathic Pain Scale (NPS).

PATIENTS AND METHODS:

Patients with PHN, painful DN, and LBP were enrolled if they had partial response to gabapentin-containing analgesic regimens and if they reported moderate-to-severe pain on the NPS at study enrollment. Eligible patients were included in an open-label, non-randomized, prospective, 2-week study across 7 clinical trial sites in the United States. The lidocaine patch 5% was applied to the area of maximal pain, using no more than a total of 4 patches changed every 24 h. Patients were maintained on their other analgesic regimens with no dose adjustment or additions allowed. Treatment effect was measured by change from baseline to Week 2 in 4 composite measures of the NPS: NPS-10, NPS-4, NPS-8, and NPS-non-allodynia. Safety was assessed by adverse events (AEs), dermal assessment of application site(s), and skin sensory testing.

RESULTS:

In the combined patient population (n = 77), 2 weeks of treatment with the lidocaine patch 5% significantly improved all 4 composite measures (p < 0.01). In the subgroup analyses, the lidocaine patch 5% demonstrated numerical advantage for all 4 NPS composite measures for the PHN patients (n = 8), and significantly improved all 4 composite measures for the painful DN patients (n = 41; p < 0.001) and LBP patients (n = 28; p < or = 0.005). Overall, 8 patients (10%) experienced mild-to-moderate treatment-related AEs.

CONCLUSIONS:

The lidocaine patch 5% effectively reduces the intensity of all common pain qualities in patients with moderate-to-severe chronic pain resulting from PHN, painful DN, or LBP. Treatment is well tolerated in combination with other analgesic regimens, with no reports of serious AEs or adverse drug interactions. Assessment scales such as the NPS may offer the possibility to differentiate between various pain states and to assess treatment outcomes for various pain qualities associated with a given pain state.

01 Jan 2004·Current medical research and opinionQ4 · MEDICINE

Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain

Q4 · MEDICINE

Article

Author: Arnold R. Gammaitoni ; Charles E. Argoff ; Mark P. Jensen ; Bradley S. Galer ; Napoleon Oleka

OBJECTIVE:

To determine the impact of the lidocaine patch 5% on pain qualities associated with low-back pain (LBP) through use of the Neuropathic Pain Scale (NPS).

PATIENTS AND METHODS:

Patients were enrolled in an open-label, non-randomized, prospective, 6-week study involving 8 clinical trial sites in the United States. Eligible patients had non-radicular LBP and reported moderate-to-severe pain on the NPS at study enrollment. Patients were stratified to 3 groups based on the duration of their LBP, defined as acute/sub-acute (< 3 months), short-term chronic (3-12 months), or long-term chronic LBP (> 12 months). The lidocaine patch 5% was applied to the area of maximal pain, using no more than a total of 4 patches changed every 24 h. Effectiveness was measured by change from baseline to Week 2 and Week 6 in 4 composite measures of the NPS: NPS-10, NPS-4, NPS-8, and NPS-non-allodynia. Safety was assessed by adverse events (AEs), dermal assessment of application site(s), and skin sensory testing.

RESULTS:

In the combined patient population (n = 71), 6 weeks of treatment with lidocaine patch 5% significantly improved all 4 NPS composite measures at both Week 2 and Week 6 (p < 0.001). Separate analyses by subgroups revealed differential improvements in the 4 composite measures. Eleven patients (15.5%) experienced treatment-related AEs that were primarily mild-to-moderate and dermal in nature.

CONCLUSIONS:

In patients with moderate-to-severe LBP, 2 weeks and 6 weeks of treatment with the lidocaine patch 5% significantly reduces the intensity of pain qualities as measured by all 4 NPS composite measures. Lidocaine patch 5% is well tolerated with few systemic AEs and may provide beneficial pain relief for patients receiving multidisciplinary treatment without increasing risks for adverse drug interactions. Pain scales such as the NPS offer the ability to measure various pain qualities experienced by LBP patients and may allow clinicians to assess the treatment impact of different medications.

100 Deals associated with NPS-4

Login to view more data